Cart
sales@molnova.com
GSK376501A
CAS No. 1010412-80-2
GSK376501A( —— )
Catalog No. M33374 CAS No. 1010412-80-2
GSK376501A is a selective and effective modulator of peroxisome proliferator-activated receptor γ (PPARγ) for the study of type 2 diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 494 | Get Quote |
|
| 5MG | 750 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGSK376501A
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK376501A is a selective and effective modulator of peroxisome proliferator-activated receptor γ (PPARγ) for the study of type 2 diabetes.
-
DescriptionGSK376501A is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator for the treatment of type 2 diabetes mellitus.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorPPAR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1010412-80-2
-
Formula Weight531.64
-
Molecular FormulaC32H37NO6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (188.10 mM; Ultrasonic )
-
SMILESO=C(O)C1=C(C=2C=CC(=CC2)C(C)(C)C)C=3C=CC=CC3N1CC=4C=C(OCCOC)C=C(OCCOC)C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kae M. Bullock, et al. Process Development and Scale-Up of a PPARγ Agonist: Selection of the Manufacture Route. Org. Process Res. Dev. 2009, 13, 2, 303-309.
molnova catalog
related products
-
Fucosterol
Fucosterol is isolated from E. stolonifera with anti-diabetic anti-adipogenic and anti-cancer activities. It regulates adipogenesis via modulation of PPARα and C/EBPα expression.
-
Rosiglitazone
A potent and selective PPARγ agonist that binds to the PPARγ ligand-binding domain with a Kd of 40 nM.
-
Ragaglitazar
Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.
